Lilly CEO: Use IT to boost drug safety

Forget FDA reform. Eli Lilly CEO Sidney Taurel (photo) wants information reform--a voluntary data-sharing collaboration among the healthcare industry, Pharma, and government. Integrated, constantly updated computer systems and databases could raise drug-safety flags much sooner, Taurel said during a sort of stump speech at the Cleveland Clinic. Vioxx's cardio side effects, for instance, could have been ID'd within three months.

Taurel admits that this sort of IT overhaul would cost up to $40 billion over 10 years. And Lilly isn't the poster child for data-sharing, considering the Zyprexa weight gain-and-blood sugar fiasco. But he's right: Healthcare has been woefully slow to adopt the sort of IT that's revolutionized other industries. Whether it can pull together now remains to be seen.

- see the release on Taurel's speech
- read the article from the Indianapolis Star

ALSO: In a deal that further underscores the growing importance of diagnostics, GE and Eli Lilly have signed a three-year agreement to study the pharmacological effects of a wide range of cancer drugs and develop in vitro diagnostic tests based on their findings. Report

Related Articles:
Eli Lilly pairs with GE to study cancer drugs. Report
Lilly developing biotech drugs the old-fashioned way. Report
Pharma, FDA to study adverse events. Report
Bickering may stall trial database. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.